ArticleAlzheimer's research & therapy2022
Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Traumatic Brain Injury and Alzheimer's Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography.Journal of neurotrauma · 2025Pooled it
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Regional differences inAnnals of nuclear medicine · 2026Article
- Evaluation of physical functioning as a marker of brain imaging outcomes in a multiethnic community-based cohort.Journal of Alzheimer's disease : JAD · 2026Article
- A study on 18F-FDG PET/CT imaging assessment of the anti-aging efficacy of BMMSCs in the macaque brain.Stem cells translational medicine · 2026Article
- Amyloid-beta statuses prediction with free water MR imaging features in Alzheimer's disease using machine learning models.BMC medical imaging · 2026Article
- Abnormal signal transmission in white matter revealed by resting-state communication connectivity in Alzheimer's disease: A comprehensive cross-sectional and longitudinal study.Translational psychiatry · 2026Article
- Motion correction of simultaneous brain PET/MR images based on tracer uptake characteristics.EJNMMI physics · 2025Article
- Article
- Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?International journal of molecular sciences · 2024Review
- High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [11C]AZD2184.Journal of Alzheimer's disease : JAD · 2024Article
- Current and Future Developments in Imaging and Treatment of White Matter Disease: A Systematic Review.Cureus · 2023Review
- Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer's disease and neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.Diagnostics (Basel, Switzerland) · 2023Article
- Amyloid-PET of the white matter: Relationship to free water, fiber integrity, and cognition in patients with dementia and small vessel disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?Frontiers in aging neuroscience · 2023Review
- A Multichannel Fluorescent Tongue for Amyloid-International journal of molecular sciences · 2022Article
- β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.NeuroImage · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET) with amyloid tracers (amy-PET) allows the quantification of pathological amyloid deposition in the brain tissues, including the white matter (WM). Here, we evaluate amy-PET uptake in WM lesions (WML) and in the normal-appearing WM (NAWM) of patients with Alzheimer's disease (AD) and non-AD type of dementia.
methodsThirty-three cognitively impaired subjects underwent brain magnetic resonance imaging (MRI), Aβ
resultsA+ compared to A- showed a higher WML load (p = 0.049) alongside higher SUVR in all brain tissues (p < 0.01). No correlations between CSF Aβ levels and WML and NAWM SUVR were found in A+, while, in A-, CSF Aβ levels were directly correlated to NAWM SUVR (p = 0.04). CSF Aβ concentration was the only predictor of NAWM SUVR (adj R
conclusionsOur data provide evidence on the role of amy-PET in the assessment of microstructural WM injury in non-AD dementia, whereas amy-PET seems less suitable to assess WM damage in AD patients due to a plausible amyloid accrual therein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.